ABUS vs PSA · P/E 5.4, rev $6.2M vs rev $4.82B
Arbutus Biopharma Corp (ABUS) versus PSA (PSA) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
PSA (PSA) common stock.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported PSA revenue for 2025-12-31 was $4.82B. Net income was $1.78B. Revenue was up 2.7% from 2024-12-31 to 2025-12-31. PSA currently screens at market cap $0.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. PSA currently screens at market cap $0.
Not investment advice. Open the ABUS and PSA stock pages for the full models.
Not investment advice.